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Inhibitor Use in Patients With No Underlying Cardiovascular Disease
Abstract
Background: Proton pump inhibitors (PPIs) are the drugs of choice when it comes to the treatment of
dyspepsia and gastroesophageal reflux disease (GERD). Recently, the FDA issued a warning regarding
concomitant use of omeprazole, a PPI, with clopidogrel as it interferes with CYP2C19 activity. The
pharmacological activity of clopidogrel is decreased, possibly increasing the potential for an acute cardiac
event. However, there is limited evidence with regards to myocardial infarct (MI) risk with use of PPIs alone.
The purpose of this review is to explore if PPI use is associated with an increased MI risk in patients with no
underlying cardiovascular disease.
Methods: An exhausted search of available medical literature was performed using MEDLINE-Ovid,
MEDLINE-Pubmed, Web of Science, and CINAHL using the keywords proton pump inhibitors, myocardial
infarction, and epidemiology. Relevant articles were assessed for validity using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) system.
Results: Four articles met eligibility criteria and were included in this systematic review. Two of the articles
were case-crossover analyses. The other two studies were a self-matched case-series design and data-mining
analysis, respectively. There were some consistent results regarding an increased MI risk with PPI use in
patients with no prior history of MI. Studies were limited with regards to the specific population in question,
actual PPI dose and compliance, and failure to control confounding factors including obesity, smoking, and
family history of coronary artery disease. Further research is warranted to address these concerns as well as the
long-term risks associated with PPI therapy.
Conclusion: There were limited studies to evaluate the subsequent risk of MI with the lone use of PPIs in
patients with no underlying cardiovascular disease. Thus far, they suggest that PPI use may be associated with
an increased risk for MI. Pending further research however, the benefits of PPI use may outweigh the risks of
adverse cardiovascular events.
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Abstract  
Background: Proton pump inhibitors (PPIs) are the drugs of choice when it comes to the 
treatment of dyspepsia and gastroesophageal reflux disease (GERD). Recently, the FDA issued a 
warning regarding concomitant use of omeprazole, a PPI, with clopidogrel as it interferes with 
CYP2C19 activity. The pharmacological activity of clopidogrel is decreased, possibly increasing 
the potential for an acute cardiac event. However, there is limited evidence with regards to 
myocardial infarct (MI) risk with use of PPIs alone. The purpose of this review is to explore if 
PPI use is associated with an increased MI risk in patients with no underlying cardiovascular 
disease. 
Methods:  An exhausted search of available medical literature was performed using MEDLINE-
Ovid, MEDLINE-Pubmed, Web of Science, and CINAHL using the keywords proton pump 
inhibitors, myocardial infarction, and epidemiology. Relevant articles were assessed for validity 
using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
system.  
Results: Four articles met eligibility criteria and were included in this systematic review. Two of 
the articles were case-crossover analyses. The other two studies were a self-matched case-series 
design and data-mining analysis, respectively. There were some consistent results regarding an 
increased MI risk with PPI use in patients with no prior history of MI. Studies were limited with 
regards to the specific population in question, actual PPI dose and compliance, and failure to 
control confounding factors including obesity, smoking, and family history of coronary artery 
disease. Further research is warranted to address these concerns as well as the long-term risks 
associated with PPI therapy.  
Conclusion: There were limited studies to evaluate the subsequent risk of MI with the lone use of 
PPIs in patients with no underlying cardiovascular disease. Thus far, they suggest that PPI use 
may be associated with an increased risk for MI. Pending further research however, the benefits 
of PPI use may outweigh the risks of adverse cardiovascular events.  
Keywords: proton pump inhibitors, myocardial infarction, epidemiology 
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Concern for Myocardial Infarction Risk Associated with 
Proton Pump Inhibitor Use in Patients With No Underlying 
Cardiovascular Disease  
BACKGROUND 
 A substantial number of physician office visits can be attributed to dyspepsia,1-3 defined 
as a chronic or recurrent pain or discomfort centered in the upper abdomen.1 Dyspepsia is a 
symptom of gastroesophageal reflux disease (GERD), which should be considered in patients 
with frequent heartburn or acid regurgitation symptoms.1 After their introduction in the 1980s,3 
proton pump inhibitors (PPIs) have been the mainstay of GERD treatment by many medical 
providers and are available over the counter. The American College of Gastroenterology 
recommends empiric PPI therapy in patients where the presumptive diagnosis of GERD can be 
established in the setting of typical heartburn and regurgitation symptoms.2 PPIs are potent 
inhibitors of gastric acid. They work by irreversibly binding to the gastric parietal cell hydrogen-
potassium ATPase pumps4,5 in the stomach decreasing the overall gastric acid production and 
thereby decreasing gastroesophageal reflux.3 PPIs are prodrugs, which means they require gastric 
acid for activation. This results in a delayed onset of acid secretion thus it is recommended that 
PPIs be taken 30 minutes prior to the first meal of the day for eight weeks.4   
In 2014, anti-ulcer agents were one of the top 20 classes of drugs prescribed globally, 
generating more than 28 billion dollars in revenue.6 Initially, they were considered to be a 
generally safe class of drugs however potentially adverse effects have been mentioned including 
nutritional deficiencies, bone fractures, and interstitial nephritis.7 Research regarding PPI safety 
has been evaluated over the last couple of years. Most recently, concern has been raised about 
the concomitant use of PPIs and clopidogrel. Clopidogrel is used in patients with a history of 
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coronary artery disease, cerebrovascular disease, and peripheral vascular disease to prevent 
further thromboembolic events from occurring. In January 2011, the US Food and Drug 
Administration issued a warning regarding the concomitant use of clopidogrel with omeprazole, 
a drug that interferes with CYP2C19 activity therefore decreasing the pharmacological activity 
of clopidogrel7 and increasing the risk of an acute thromboembolic event.  
As the safety of PPI use in patients with underlying cardiovascular disease has prompted 
FDA warnings, the risk of adverse cardiac events connected with PPI use amongst the population 
with no prior history of myocardial infarction (MI) is unknown. Moreover, symptoms of GERD 
including dyspepsia, epigastric pain, and nausea can overlap with other conditions,2 including 
cardiac chest pain. With PPIs currently available over the counter, it is imperative that the 
symptoms of GERD be distinguished from that of an acute MI. The aim of this review is to find 
out if PPI use is associated with an increased MI risk in patients with no underlying 
cardiovascular disease. 
METHODS 
An exhaustive search of available medical literature was performed using MEDLINE-
Ovid, MEDLINE-Pubmed, Web of Science, and CINAHL using the keywords proton pump 
inhibitors, myocardial infarction, and epidemiology. The search was narrowed to include studies 
published in the English language and conducted on humans. Studies examining cardiovascular 
and gastrointestinal bleeding risk with regards to aspirin and clopidogrel use were excluded. The 
bibliographies of the articles were reviewed for additional sources. Relevant articles were 
assessed for validity using the Grading of Recommendations Assessment, Development, and 
Evaluation (GRADE) system.8 
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RESULTS 
A total of 201 articles were found in the initial search. For the purpose of this study, 
focus was drawn to the use of proton pump inhibitors and the risk of myocardial infarction in 
patients without underlying cardiovascular disease. After screening those articles using the 
search terms and exclusion criteria, four studies9-12 satisfied all the inclusion criteria and were 
included in this systematic review. See Table 1. 
Shih et al 
 Shih et al9 conducted two different study designs. The first was a propensity-score 
matched analysis between PPI users and non-users to adjust for confounding factors such as age, 
sex, comorbidities and concomitant drug use. Patients included were 18-80 years of age with no 
prior history of MI, acquired immunodeficiency syndrome, human immunodeficiency virus, 
cancer prior to PPI prescription, or antecedent PPI prescription within 120 days of the study. All 
patients received a PPI prescription after diagnosis of peptic ulcer, duodenal ulcer, GERD by 
positive pan-endoscopy. Excluded were patients who received a PPI prescription within 60 days 
of an episode of severe upper GI bleeding requiring hospitalization, blood transfusion, or use of 
inotropic agent due to the presumed increase MI risk following these events.9 
 The primary outcome was incidence of MI. A total of 126 367 PPI users were matched 
with 126 367 non-PPI users. Groups were homogenous with regards to age, gender, concomitant 
medications, and coexisting conditions. After the 120-day follow up period, 79 of the PPI users 
experienced an MI compared with 50 of the non-PPI users. MI risk was calculated as 1.58% 
greater amongst PPI users (95% CI = 1.11-2.25; P = 0.011). Interaction tests compared effects 
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across subgroups including age, gender, diabetes mellitus, use of antiplatelet agents, use of 
clopidogrel specifically, and use of NSAIDs showing no statistically significant results.9 
The second study design conducted was a case-crossover analysis to identify the 
association between PPI use and MI. This study design allowed for patients to serve as their own 
controls thereby reducing the effects of confounding elements such as race, body mass index, 
smoking status, and lifestyle. Calculations of MI risk were also performed in comparison to two 
drug controls. H2RA (Histamine-2 receptor antagonists) served as the negative control avoiding 
confounding by indication and NSAIDs served as the positive control. Index date was defined as 
the first day of hospitalization. The odds ratio (OR) for MI risk following drug exposure was 
estimated by the ratio of patients who were exposed to that drug 1-7 days before the index day to 
those who were only exposed to the drug 8-14 days before the index date.9 
 In the case-crossover analysis, 5430 patients 18-80 years of age who were hospitalized 
between 2000 and 2009 for an MI were identified. Those with a prior history of MI, those who 
were hospitalized within 60 days prior to the start of the study, and who had a history of severe 
acute GI bleeding were excluded. In the 7-day window, 109 PPI users experienced an MI 
compared to 75 in the control group. For the 14-day window, 114 PPI users experienced an MI 
in compared to 78 in the control group. Analysis revealed PPI use was associated with an 
increased MI risk for both the 7-day (Adjusted OR = 4.61, 95% CI = 1.76-12.07, P = 0.002) and 
14-day (Adjusted OR= 3.47, 95% CI = 1.76-6.83, P < 0.001) periods. 9 See Table II. 
 The authors concluded that both study designs performed demonstrate there is an 
increased MI risk amongst PPI users versus non-PPI users, even in those without a prior history 
of MI. An important limitation to consider is confounding by indication. The concern is that 
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more prescriptions for PPI are given to high-risk patients who would misinterpret abdominal 
pain as a sign of an MI. To minimize this, H2RA were examined as they are prescribed based on 
the same symptomatology and showed no increased MI risk. However, in this study, PPI 
prescriptions were prescribed to patients with GI diseases diagnosed per endoscopy. The 
propensity score analysis only observed patients for 120 days therefore further investigation of 
the long term cardiovascular effects of MI may be warranted. Despite using the case-crossover 
analysis to control for elements such as race, body mass index, smoking status, and lifestyle 
other potential confounding factors including obesity, smoking, alcohol, and family history of 
heart disease were not included in the analysis. Despite these inherent limitations, the authors 
thought it would unlikely change the risk during a short period of time and findings 
demonstrated that short-term PPI exposure was still associated with an increased risk of MI. 
However, with a calculated number needed to harm (NNH) of PPI users to be 4357, the authors 
state that the benefits of PPI therapy outweigh the risk of MI.9 
Turkiewicz et al 
 Turkiewicz et al11 performed two case-crossover analyses. The first case-crossover 
analysis was to compare if the prescription of PPIs was more frequent during the 3-day period 
preceding the first day of the MI hospitalization, defined as the hazard period, compared to the 
thirty 3-day periods preceding the hazard period, defined as the control period. The second case-
crossover analysis compared the dispensation of PPIs to the aforementioned hazard and control 
periods. The authors then repeated the analyses in a subgroup of patients with no history of prior 
MI.11 
 12 
Utilizing the Swedish Population Register and Skåne Healthcare Register, 3490 patients 
40-90 years of age with incident of acute MI between October 2005 and December 2006 were 
identified. The prescription of PPIs during the hazard period was not conclusively higher 
compared to that in the control periods with an OR of 1.36 (95% CI = 0.82-2.25). However, in 
patients with no history of acute MI, the risk of PPI prescriptions was conclusively elevated with 
an OR of 1.66 (95% CI = 1.00-2.76). When the dispensation date was used, the OR of having a 
PPI dispensed during the hazard period compared to the control in all cases of MI as well as 
those with no history of prior MI.11 See Table III. 
 To explain the observed increase in PPI prescriptions prior to MI, the authors discussed 
that MI symptoms may be misinterpreted as those of dyspetic conditions. This is supported by 
the diluted effect when dispensation date is used instead of prescription date. Authors discuss 
that their study maybe limited due to small sample size. In addition, they did not measure the 
actual exposure to the medication.11 
Juurlink et al 
 Jurrlink et al10 conducted a self-matched case-series method to analyze the association of 
PPI therapy initiation with MI and heart failure (HF). This study design allows patient to serve as 
their controls to reduce confounding by fixed patient factors. Included were Ontario residents 66 
years of age and greater who were hospitalized within 12 weeks of initiating PPI therapy. Index 
date was defined as the first date of the PPI prescription. Excluded were patients discharged from 
the hospital after 3 days under the assumption that a true MI was unlikely. In the primary 
analysis, patients who were hospitalized for acute MI or HF within 1 year of the index date were 
included. A secondary analysis was performed and limited to patients who were alive at the end 
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of the 12-week follow up period. Additional analyses examined the risk of hospitalization in 
patients who were hospitalized for MI or HF 6-12 months preceding the initiation of PPI 
therapy.10  
Follow-up periods were divided into three 4-week intervals. The first 4-week period was 
considered the primary risk interval and followed the initiation of PPI prescription. The final 4-
week interval was defined as the control interval. Tracer analyses for H2RA and benzodiazepines 
were performed. Neither of these drugs classes have a plausible link to adverse cardiac events 
therefore the authors reasoned a null finding with these drugs would enhance the argument for a 
cause-and-effect relationship with regards to the main analysis. Lastly, all analyses were 
replicated using risk and reference intervals of two-week duration rather than four, separated by 
a two-week washout period.10 
The 13-year study period revealed 5550 hospitalizations for an acute MI within 12 weeks 
initiation of PPI therapy. Patients had a mean age of 77 years, 49% were female, and 956 died 
during the 12-week observation. The OR of hospitalization due to an MI during the risk interval 
versus the control interval was 1.8 (95% CI = 1.7-1.9) for all MI cases. Amongst patients with no 
history of acute MI, the risk was slightly higher at an estimated OR 2.1 (95% CI = 1.6-2.7). 
There were 6003 patients were hospitalized for HF within 12 weeks of the initiation of PPI 
therapy. Patients had a mean age of 80 years, 55% were female, and 1235 died during follow-up. 
The OR of HF during the primary risk interval was 1.8 (95% CI = 1.7-1.9). The risk was similar 
among patients with a history of HF. Similar results were found with regards to the risk of 
hospitalization for MI or HF in patients without history of the disease within 12 weeks of the 
initiation of H2RA (OR = 1.8, 95% CI = 1.7-1.9) or benzodiazepines (OR =1.3, 95% CI = 1.3-
1.4).10 See Table IV for further clarification. 
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Since omperazole is known to interfere with the bioactivation of clopidogrel, this study 
specifically focused on the association between omeprazole use and MI or HF. A calculated OR 
of 1.6 (95% CI = 1.6-2.0) was found. The study found this to be no different compared to 
pantoprazole, another PPI which does not affect the clopidogrel response. In patients taking 
clopidogrel at the initiation of PPI therapy, there was no increased risk of MI or HF found.10 
The authors discussed a higher risk of hospitalization for acute MI or HF was found in 
older subjects following the initiation of PPI therapy. A similar risk was also discovered with 
regards to H2RA and benzodiazepines, drugs with no plausible causal link to adverse cardiac 
effects. Together, these findings imply an unlikely cause-and-effect explanation for the observed 
association between PPIs and adverse cardiac events.10  
Jurrlink et al10 concluded there to be an increased risk of acute MI or HF in the short term 
following the initiation of PPI therapy. However, similar risk was seen in other drugs without 
known cardiotoxicity. Limitations of this study include the concern for protopathic bias however 
it does not explain the associated between benzodiazepines and adverse cardiac events. The 
study also only examined the short-term effects of PPI therapy. Further investigation is 
warranted to exam the long-term effects. It should be considered that PPI therapy is often 
intermittent suggestive that long-term follow-up could be less reliable. There is also lack of 
information on drug dose, adherence, and risk factors for cardiac disease including obesity and 
smoking.10 
Shah et al    
 Shah et al12 conducted a data-mining design to screen if exposure to PPIs was associated 
with an elevated MI risk. This design used variables to predict the responses and should not be 
interpreted as a causal regression models, as is the goal with epidemiological studies.12 Data was 
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obtained from the Stanford Translational Research Integrated Database Environment from 1994-
2012 as well as Practice Fusion, Inc., an electronic based health record, from 2007-2012. Patients 
included were 18 years of age and greater with GERD as defined by ICD-9 codes for 
gastroesophageal reflux, heartburn, and the UMLS code for gastroesophageal reflux. Two study 
groups were defined. The primary group was the defined by patients taking PPIs, including a 
sub-group of patients who were not on clopidogrel. Six PPIs (omeprazole, lansoprazole, 
pantoprazole, esomeprazole, rabeprazole, and dexansoprazole) were studied as a class. Five of 
the six were studied individually with the exception of dexlansoprazole from the individual 
analysis due to lack of exposure. H2RA (cimetidine, famotidine, nizatidine, and ranitidine) were 
examined as an alternative treatment for GERD in separate analysis. Controls were selected 
using propensity score matching from the baseline population. The outcome of interest was MI 
as defined by ICD-9 code for acute MI and more than 18 UMLS codes including myocardial 
infarction and silent myocardial infarction. Excluded were patients less than 18 years of age at 
the first mention of GERD.12 
Authors reported a 97.5% specificity and 39% sensitivity in discerning a true association. 
It provided an 89% accuracy with a positive predictive value of 81% when an equal number of 
true and false associations are tested. Results demonstrated an adjusted OR of 1.16 (95% CI = 
1.09-1.24) of PPIs as a class with MI. When clopidogrel was excluded, the association persisted 
across the groups with an adjusted OR of 1.14 (95% CI = 1.06-1.24). H2RA on the other hand 
had an adjusted OR of 0.93 (95% CI = 0.86-1.02).12 See Table V. 
Additionally, the authors prospectively examined the cardiovascular mortality in the 
GENE PAD (the Genetic Determinants of Peripheral Arterial Disease) study with the association 
of PPI use at enrollment. This study was independent of the text-mining approach. This cohort of 
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patients underwent an elective, non-emergent coronary angiogram secondary to angina, shortness 
of breath, or abnormal stress test. Within a median follow up period of 5.2 years, there were 58 
cardiovascular mortalities. Cardiovascular mortality was defined as MI, cardiac arrest, stroke, 
heart failure, and aneurysm rupture. Unadjusted analysis using a Cox proportional hazard model 
showed a hazard ratio of 2.22 (95% CI 1.19-4.16; P = 0.013) with a 122% increased 
cardiovascular mortality risk among PPI users. When controlling for several cardiovascular 
comorbidities, the association persisted with a hazard ratio of 2.00 (95% CI = 1.07-3.78; P = 
0.031). No association was found with H2RA in both the unadjusted and adjusted analysis.12  
The authors concluded there to be an elevated MI risk in the general population whom 
take PPIs versus H2RA. This was association was independent of clopidogrel use and seen in 
non-elderly patients without an underlying history of acute coronary syndrome. As an 
observational study, data may be subject to confounding. Other limitations to their study were 
the unknown use of over the counter PPIs as well as differences in drug dosages. They were 
unable to control for factors such as obesity and insulin resistance. Additionally, the authors state 
that it is possible PPI use may reflect a generally sicker patient population.12  
DISCUSSION 
This review aimed to investigate the risk of MI in patients taking PPIs for treatment of 
GERD with no underlying cardiovascular disease. In the four reviewed studies, 9-12  authors 
examined whether or not PPI use was associated with an MI risk. Shih et al9 and Juurlink et al10 
matched PPI prescriptions with hospitalizations for MI and HF, respectively, while Turkiewicz et 
al11 explored the prescription date and medication dispensation with hospitalizations for MI, and 
Shah et al12 used a data-mining approach to screen if PPI exposure was associated with an MI. 
All studies concluded there to be an increased MI risk with PPI use, particularly in patients with 
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no underlying history of MI. For the Shih et al,9 the MI risk was 1.58-fold greater in PPI users 
versus non-users in the propensity-score analysis. In their case-crossover design, this risk 
persisted and PPI use 7-days prior to hospitalization for MI with an adjusted OR of 4.61 (95% CI 
= 1.76-12.07, P = 0.001). More notable was that this risk was also significant at 14-days prior to 
hospitalization at 3.47 (95% CI = 1.76-6.83, P < 0.001). Turkiewicz et al11 found there to be a 
slightly increased risk of MI after PPI prescription in patients with no history of prior MI. When 
dispensation date was used, there was no increased risk of MI in patients with and without a 
history of prior MI. Juurlinnk et al10 found an increase in cardiovascular events amongst PPI 
users with no history of prior cardiovascular events. They did note the risk for MI was slightly 
elevated in patients with a prior history or MI. Shah et al12 also found there to be an adjusted OR 
of 1.16 (95% CI = 1.09 – 1.24) for PPIs as a class with MI.  
 H2RA were explored as an alternative to PPI treatment by by Shih et al,9 Juurlink et al,10 
and Shah et al.12 Both Shih et al9 and Shah et al12 found no increased MI risk with H2RA use. 
Juurlink et al10 however noted an increase in cardiovascular events with H2RA as well as 
benzodiazepines, another drug without known cardiotoxicity. With this finding, they concluded 
that their results of increased MI risk with PPI use could not represent a cause-and-effect 
relationship. In comparison to the two other studies, Juurlink et al10 had a smaller sample size 
and included patients 66 years of age and greater. Only those who had had an MI or HF within 1 
year preceding the PPI prescription date were excluded. In these patients with a cardiovascular 
history occurring greater than 1 year prior to study date, they were found to have an increased 
risk of MI with PPI use. It is concerning that their subjects represent a sicker patient population.  
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 The main limitations of these studies included in this systematic review of literature are 
analysis of drug dosage and compliance, long-term risk analysis, exploration of patients with no 
prior cardiovascular events, and controlling for confounding comorbid conditions including 
obesity, smoking, and family history of cardiovascular disease. No study specifically mentioned 
the PPI drug dose, frequency, and patient compliance therefore true drug exposure remains 
questionable. It remains unknown if the increase seen in PPI prescriptions prior to MI is due to 
misinterpretations of dyspeptic symptoms for acute coronary syndrome. With PPI prescriptions 
now available over the counter, it is crucial that medical providers educate patients on the signs 
and symptoms of GERD versus acute coronary symptoms.  
While the systematic review demonstrated an increased MI risk with PPI use, the 
mechanism of action by which this occurs and conditions which may put a patient at risk for 
such adverse cardiac events remains unclear. Turkiewicz et al11 and Shah et al12 analyzed PPI use 
with MI however did not specifically mention whether or not patients had a prior history of MI. 
Juurlink et al10 on the other hand included patients with a history of MI or HF who were 
hospitalized for these conditions greater than a year from the index date. Further analysis is 
needed to evaluate MI risk in patients with no history of MI and controlling for confounding 
comorbid conditions including obesity, smoking, and family history of cardiovascular disease.  
Future studies should explore the investigation of proinflammatory markers, such as 
dimethylarginine dimethylaminohydrolase (DDAH), 12 and PPI use and whether or not 
pharmacological interactions exist. All studies also examined short-term effects of PPI use 
warranting further investigation as to the long-term cardiovascular events. In addition to further 
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examination of the cardiovascular effects of PPIs, further research should aim to evaluate the risk 
with alternative treatments such as H2RA.  
Although evidence is limited with regards to this specific population in question, what is 
available suggests a possible relationship exists between PPI use and MI. The current collection 
of evidence is not strong enough to warrant a change in GERD treatment guidelines due to the 
aforementioned limitations in the reviewed studies. With a calculated NNH of 4357 per Shih et 
al,9 clinicians should consider the benefits of PPI treatment to outweigh the risk of adverse 
cardiac events.  
CONCLUSION 
 There is some evidence presented in the case-crossover and data-mining analysis of an 
increased risk of MI with the use of PPI. With a calculated NNH of 4357,9 the current collection 
of evidence is not strong enough to warrant a change in GERD treatment guidelines due to 
limitations in the reviewed studies. Further studies should examine actual PPI use, dose of the 
medication, patient compliance, and outcome measurements for both short-term and long-term 
checkpoints.  
Other factors warranting further investigation include comparison amongst subgroups 
known to be at a higher cardiovascular risk including those with obesity, diabetes, tobacco use, 
and family history of coronary artery disease. Comparisons should further investigate H2RA and 
whether there is a risk for cardiovascular events or if it is an acceptable alternative in patients 
who are at a higher risk for adverse cardiovascular events. However, as PPI use alone has been 
shown to have an increased MI risk in patients without prior MI, medical providers should take 
the time to properly educate patients of the early signs and symptoms of an MI, especially as this 
 20 
medication is available over the counter. In addition, medical providers should also strongly 
consider whether or not to use PPIs in patients with a high risk for adverse cardiac event 
compared to other alternatives without shown adverse cardiotoxicity.  
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Table I: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Shih et al5 Propensity score 
matching analysis and 
case-crossover analysis 
Seriousa Not Serious Not Serious Not Serious Unlikely None Very 
low 
Turkiewicz 
et al7 
Case-crossover design Seriousb Not Serious Not Serious Not Serious Unlikely None Very 
low 
Juurlink et 
al6 
Self-matched case 
series 
Seriousc Not Serious Not Serious Not Serious Unlikely None Very 
low 
Shah et al8 Data-mining Seriousb Not Serious Not Serious Not Serious Unlikely None Very 
low 
a Lack of addressing possible confounders 
bLack of appropriate eligibility criteria (vague exclusion criteria) 
c Primary analysis excluded patients with previous hospitalization for AMI or HF within one year of the preceding index, all patients 
>66 years 
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Table II: Shih et al Summary of Findings9 
 Case 
N = 5430 
Control 
N = 5430 
AOR 95% CI P value 
7 day window      
PPI 109 75 4.61 1.76-12.07 0.002 
H2RA 172 144 1.16 0.79-1.70 0.452 
NSAIDs 722 590 1.55 1.27-1.89 <0.001 
14 day window      
PPI 114 78 3.47 1.76-6.38 <0.001 
H2RA 247 203 1.30 0.96-1.74 0.085 
NSAIDs 879 702 1.74 1.47-2.06 <0.001 
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval 
Table III. Turkiewicz et al Summary of Findings11 
 All MI Cases No History of Prior MI 
 OR 95% CI OR 95% CI 
PPI Prescriptions 1.36 0.082-2.25 1.66 1.00-2.67 
PPI Dispensation 1.25 0.92-1.72 1.29 0.92-1.72 
 
Table IV. Juurlink et al Summary of Findings10 
 All MI Cases History of Prior MI All HF Cases History of Prior HF 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
PPI Initiation  1.8 1.7-1.9 2.1 1.6-2.7 1.8 1.7-1.9 1.8 1.4-2.2 
 MI cases (No History of Condition) HF (No History of Condition) 
 OR 95% CI OR 95% CI 
H2RA 1.8 1.7-1.9 1.5 1.4-1.6 
Benzodiazepines 1.3 1.3-1.4 1.6 1.5-1.7 
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Table V. Shah et al Summary of Findings12 
 OR 95% CI 
PPIs (class) 1.16 1.09-1.24 
H2RA (class) 0.93 0.82-1.02 
 
